14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.0560 $0.0799 Friday, 3rd May 2024 ARDS stock ended at $0.0615. This is 4.24% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 8.47% from a day low at $0.0590 to a day high of $0.0640.
90 days $0.0560 $0.0850
52 weeks $0.0500 $0.540

Historical Aridis Pharmaceuticals Inc. prices

Date Open High Low Close Volume
May 03, 2024 $0.0640 $0.0640 $0.0590 $0.0615 28 923
May 02, 2024 $0.0617 $0.0623 $0.0588 $0.0590 37 092
May 01, 2024 $0.0620 $0.0620 $0.0580 $0.0588 51 906
Apr 30, 2024 $0.0571 $0.0670 $0.0570 $0.0600 67 140
Apr 29, 2024 $0.0620 $0.0670 $0.0566 $0.0566 32 560
Apr 26, 2024 $0.0630 $0.0650 $0.0581 $0.0650 24 351
Apr 25, 2024 $0.0600 $0.0650 $0.0600 $0.0650 7 762
Apr 24, 2024 $0.0635 $0.0670 $0.0605 $0.0630 29 800
Apr 23, 2024 $0.0620 $0.0635 $0.0560 $0.0635 148 984
Apr 22, 2024 $0.0625 $0.0669 $0.0600 $0.0645 41 230
Apr 19, 2024 $0.0610 $0.0669 $0.0600 $0.0600 113 915
Apr 18, 2024 $0.0625 $0.0633 $0.0600 $0.0615 407 922
Apr 17, 2024 $0.0700 $0.0720 $0.0646 $0.0660 27 515
Apr 16, 2024 $0.0765 $0.0765 $0.0674 $0.0705 19 512
Apr 15, 2024 $0.0729 $0.0740 $0.0680 $0.0700 101 210
Apr 12, 2024 $0.0695 $0.0729 $0.0667 $0.0717 37 003
Apr 11, 2024 $0.0725 $0.0768 $0.0660 $0.0735 163 046
Apr 10, 2024 $0.0670 $0.0770 $0.0660 $0.0769 135 586
Apr 09, 2024 $0.0710 $0.0780 $0.0671 $0.0672 69 126
Apr 08, 2024 $0.0690 $0.0769 $0.0675 $0.0680 44 173
Apr 05, 2024 $0.0721 $0.0780 $0.0664 $0.0765 48 915
Apr 04, 2024 $0.0799 $0.0799 $0.0715 $0.0715 109 471
Apr 03, 2024 $0.0728 $0.0780 $0.0715 $0.0716 28 087
Apr 02, 2024 $0.0715 $0.0770 $0.0715 $0.0730 10 153
Apr 01, 2024 $0.0780 $0.0780 $0.0715 $0.0715 57 203
Click to get the best stock tips daily for free!

About Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals. Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-32... ARDS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT